Blood Cancer Talks Episode 51. Venetoclax in AML with Dr. Andrew Wei
69 snips
Sep 27, 2024 Dr. Andrew Wei, a leading expert in acute myeloid leukemia from the Peter McCallum Cancer Center, discusses the innovative use of venetoclax in treating AML. He highlights groundbreaking clinical trials that have transformed treatment pathways, particularly for older patients. Innovative therapies like venetoclax combined with hypomethylating agents are explored, along with ongoing resistance challenges and the role of genetic mutations in personalized treatment. The conversation also touches on the implications of minimal residual disease negativity in enhancing patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Career Shift
- Andrew Wei initially planned a fellowship in England but chose to pursue a PhD in apoptosis.
- This decision was influenced by a colleague's suggestion and his future wife.
Azacitidine Plus Venetoclax
- Venetoclax plus azacitidine is a powerful combination, distinct from azacitidine alone.
- Consider its myelotoxic potential similar to intensive chemotherapy.
Bone Marrow Assessment Timing
- Assess bone marrow on day 21 for inpatients to confirm blast clearance and adjust treatment.
- For outpatients, consider bone marrow assessment based on individual risk factors.